Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Scleromyxedema].

M Neufeld1, C Sunderkötter2,3, R K C Moritz3

  • 1Abteilung für translationale Dermatoinfektiologie, Westfälische Wilhelms-Universität Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland. Matthias.Neufeld@ukmuenster.de.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|August 24, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dermatologie (Heidelberg, Germany)·2025
Same author

Dermatologie (Heidelberg, Germany)·2025
Same author

Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients.

Experimental dermatology·2024
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

[Progressive sclerodactyly in a Gambian farmer].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021
Same author

Alemtuzumab-induced halo naevus-like hypopigmentation - new insights into secondary skin autoimmunity in response to an immune cell-depleting antibody.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
See all related articles

Scleromyxedema is a rare, progressive disorder affecting multiple organ systems, often linked to monoclonal gammopathy. While its cause is unknown, treatments like immunoglobulin therapy and stem cell transplantation are used, but long-term management is crucial due to common recurrences.

Area of Science:

  • Dermatology
  • Immunology
  • Hematology

Background:

  • Scleromyxedema is a rare connective tissue disease characterized by skin thickening and extracutaneous manifestations.
  • It is frequently associated with monoclonal gammopathy, suggesting an underlying immune system dysregulation.
  • The pathogenesis remains largely unknown, contributing to the lack of approved therapeutic options.

Purpose of the Study:

  • To summarize the current understanding of scleromyxedema, including its clinical presentation, associated conditions, and management strategies.
  • To highlight the challenges in treating this rare disorder and the need for effective, evidence-based therapies.
  • To emphasize the importance of long-term monitoring and maintenance therapy due to the high recurrence rate.

Main Methods:

Keywords:
Generalized papular and sclerodermoid mucinosisIntravenous immunoglobulinsLichen myxoedematosusMonoclonal gammopathyMucinosis

Related Experiment Videos

  • This abstract synthesizes information from existing literature on scleromyxedema.
  • It reviews clinical findings, extracutaneous involvement, and current treatment approaches.
  • The summary focuses on the chronic and progressive nature of the disease and its management.

    • Main Results:

    • Scleromyxedema presents with characteristic waxy papules and indurated plaques, leading to reduced mobility.
    • Extracutaneous manifestations can affect the musculoskeletal, cardiovascular, gastrointestinal, respiratory, and renal systems.
    • Current treatment options include high-dose immunoglobulins, lenalidomide/thalidomide, systemic glucocorticosteroids, and autologous stem cell transplantation.

    Conclusions:

    • Scleromyxedema is a severe, chronic condition requiring multidisciplinary management.
    • Effective treatment often involves a combination of therapies and long-term maintenance.
    • Close clinical follow-up is essential to manage recurrences and monitor disease progression.